Compare BIRD & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIRD | MRKR |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 27.7M |
| IPO Year | 2021 | 2010 |
| Metric | BIRD | MRKR |
|---|---|---|
| Price | $3.99 | $1.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 60.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.22 | ★ 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.12 | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $0.81 |
| 52 Week High | $24.31 | $4.07 |
| Indicator | BIRD | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 45.74 |
| Support Level | $3.85 | $1.34 |
| Resistance Level | $4.55 | $1.52 |
| Average True Range (ATR) | 0.47 | 0.07 |
| MACD | -0.34 | -0.01 |
| Stochastic Oscillator | 4.61 | 21.74 |
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.